My Watchlist

BNY Mellon Municipal Income Inc. Common Stock

BNY Mellon Strategic Municipal Bond Fund, Inc. Common Stock

BNY Mellon Strategic Municipals, Inc. Common Stock

Big Digital Energy, Inc. - Common Stock

CorVel Corp. - Common Stock

Cwc Energy Services Corp

DEFSEC Technologies Inc. - common stock, no R/S concurrent with offering

FAT Brands Inc. - 8.25% Series B Cumulative Preferred Stock

FAT Brands Inc. - Class B Common Stock

FAT Brands Inc. - Warrant

Hikma Pharmaceuticals Plc.

Infrastructure and Energy Alternatives, Inc. - Common Stock

Iveda Solutions, Inc. - Common Stock

Kronos Worldwide Inc Common Stock

Livongo Health, Inc. - common stock

NLI Holdings, Inc. Common Stock

Navan, Inc. - Class A Common Stock

Nuveen Churchill Direct Lending Corp. Common Stock

State Street SPDR Dow Jones REIT ETF

TransUnion Common Stock

Valhi, Inc. Common Stock

Vinci Compass Investments Ltd. - Class A Common Shares

Vista Outdoor Inc. Common Stock

Edit Watchlist

Top Indices

Dow Jones Industrial Average

NASDAQ Composite

Standard & Poors 500

My Portfolio

Articles published by Mirum Pharmaceuticals, Inc.

< Previous 1 2 3 4 5 6 7 8 Next >

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 08, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 10, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

Mirum Pharmaceuticals to Present at SVB Leerink 11th Annual Global Healthcare Conference

February 09, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones

January 11, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 10, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022

January 04, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

Mirum Pharmaceuticals Added to NASDAQ Biotechnology Index

December 15, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

LIVMARLI (maralixibat) Presentations Show Improvements in Quality of Life Measures in Alagille Syndrome and PFIC2 at NASPGHAN Annual Meeting 2021

December 13, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

Mirum Pharmaceuticals to Present LIVMARLI™ (maralixibat) Analyses at NASPGHAN 2021 Annual Meeting

December 06, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

November 22, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher

November 17, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

November 15, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

Six-Year Natural History Comparison with Mirum’s LIVMARLI (maralixibat) Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with Alagille Syndrome

November 15, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

Mirum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call on November 15, 2021

November 08, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

New LIVMARLI™ (maralixibat) Data to be Showcased at AASLD The Liver Meeting® 2021

November 01, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

The Lancet Publishes Data From Mirum Pharmaceuticals' ICONIC Pivotal Study of Maralixibat (LIVMARLI) Treatment in Alagille Syndrome

November 01, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older

September 29, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan

September 21, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM TAK

Mirum Pharmaceuticals Submits European Marketing Authorization Application for Maralixibat in Alagille Syndrome Supported by New Positive Results from Natural History Study Comparison

September 13, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 10, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

Mirum Pharmaceuticals to Participate in September Investor Conferences

September 02, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

Mirum Pharmaceuticals Appoints Biotechnology Executive William C. Fairey to its Board of Directors

August 19, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 10, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

August 05, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

Mirum Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021

July 29, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

Mirum Pharmaceuticals and GC Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in South Korea

July 26, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 12, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

Mirum Pharmaceuticals to Present at Piper Sandler’s Virtual EASL Takeaway Day

June 24, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

Mirum Pharmaceuticals Presents Analyses From Its Rare Liver Disease Programs at the EASL International Liver Congress 2021

June 23, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

Mirum Pharmaceuticals to Showcase Analyses From Its Rare Liver Disease Programs at The International Liver Congress 2021

June 16, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Tickers MIRM

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.